CART-PSMA Cells for Advanced Prostate Cancer

This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.

Trial Details

NCT ID
NCT05656573
Phase
PHASE1
Sponsor
Nova Therapeutics LLC
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • CART-PSMA cells
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • All participants must have the ability to understand and the willingness to sign a written informed consent.
  • Histologic confirmation of prostate cancer.
  • Tumor expressing PSMA as demonstrated by immunohistochemistry analysis or other methods.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →